All News
‼️FAP (fibroblast activation protein)
PET-CT in PsA‼️
⚡️synovial and entheseal accum in PsA v HC
⚡️correlation of uptake with pain scores
⚡️IL-17A ⬇️ FAP, with arrest joint damage
⚡️persistent FAP - ⬆️ prog joint damage
❓new T2T in PsA❓
#ACR22 @RheumNow Abst#1602
Patricia Harkins DrTrishHarkins ( View Tweet)
Gut microbiota of axSpA pts who underwent bDMARD tx for one year more closely resembled controls. Unique enrichment of Collinsella in axSpA patients remained stable across time & tx, suggesting it may be a disease biomarker. Abs 1162 #ACR22 @RheumNow https://t.co/SjwORWp6IU https://t.co/rLlu4jGCfd
Dr. Rachel Tate uptoTate ( View Tweet)
How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves?
Survey shows <50% rheum collaborate with derm
Need updated EMRs and additional education
Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS
Robert B Chao, MD doctorRBC ( View Tweet)
⚡️PRESTO⚡️
📈PsA prediction tool in psoriasis
Risk of PsA at 1yr ⬆️:
👉younger
👉male
👉FHx Psoriasis
👉back stiffness
👉stiffness level
👉nail pitting
👉biologic use
👉⬆️ pain and global health
(AUC 72.3,95%CI 65.5,79.1)
#ACR22 @RheumNow Abst#1612
Patricia Harkins DrTrishHarkins ( View Tweet)
Plenary:
Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity
Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl
Dr. Antoni Chan synovialjoints ( View Tweet)
Plenary:
Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
◦ Favourable safety profile
◦ Well-tolerated over 24 Wks
◦ Improved ESSDAI, salivary flow, Igs
◦ May be first effective oral disease-modifying therapy for SS
Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI
Dr. Antoni Chan synovialjoints ( View Tweet)
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence.
https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W
Links:
Dr. John Cush RheumNow ( View Tweet)
Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts?
Single-center (n=126) with one MTX dose WH post-each vaccine
Similar humoral response
Big error bars suggest other factors more important
ABST0913 #ACR22 @RheumNow
(not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY
David Liew drdavidliew ( View Tweet)
Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU
Richard Conway RichardPAConway ( View Tweet)
GM-CSF inc'd in active AS pts, particularly in younger ages, and strongly correlates with disease activity, but not with disease duration. TNFi tx does not affect GM-SCF levels, despite improving disease activity. Abs 1156 #ACR22 @RheumNow https://t.co/ndhBGbPsCw
Dr. Rachel Tate uptoTate ( View Tweet)
Don't forget the power of NSAIDs! (esp COX2i)
10 year study from Germany.
NSAID intake associated with lower radiographic progression in axSpA patients (esp r-axSpA)
COX2i may have stronger effect
#ACRBest #ACR22 @RheumNow Abs#1492 https://t.co/vPIaCahmiW
Robert B Chao, MD doctorRBC ( View Tweet)
Prevalence of uveitis in patients with PsA was about 5%. Uveitis rate decreased w/ anti-TNFα monoclonal antibodies and increased w/ ETN and SECU. Abs 1159 #ACR22 @RheumNow https://t.co/BtHMQ6apNI https://t.co/uZEYVQdiOU
Dr. Rachel Tate uptoTate ( View Tweet)
Corriere et al Duloxetine and gabapentin have similar rates of MI and stroke in non-cancer pain. There was some theoretical concern that duloxetine could increase risk but not evident here @RheumNow #ACR22 Abstr#1195 https://t.co/E3S9Md5XWq https://t.co/8KMtcU6d1B
Richard Conway RichardPAConway ( View Tweet)
Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz
Richard Conway RichardPAConway ( View Tweet)
Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies.
@RheumNow #ACR22
https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu
Julian Segan JulianSegan ( View Tweet)
Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade
🔸MASTER strategy-optimal reference strategy: IBP, ✅NSAID response, HLA-B27+ & +SpA family hx
🔸Clinical predictive factors: uveitis, IBP, Pso, enthesitis &🚹
#ACR22 @RheumNow ABST#1512 #ACRBest https://t.co/l6AleXX7Kt
sheila RHEUMarampa ( View Tweet)
Decreased colonic mucus production in HLA-B27 + healthy individuals and axSpA and IBD pts. Abs 1151 #ACR22 @RheumNow https://t.co/CwX4n6PJFy https://t.co/4f1Za0Qhpj
Dr. Rachel Tate uptoTate ( View Tweet)
Biologics to treat gut microbiome dysbiosis??
In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls.
Collinsella remained stable - possible biomarker?
Abs#1162 @RheumNow #ACR22
#ACRBest https://t.co/vmQFJMpNPP
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic progression in men may be mediated by S100 proteins and prostaglandins. @RheumNow https://t.co/mWbsaB8kK8 https://t.co/IkTBZcaqa6
Dr. Rachel Tate uptoTate ( View Tweet)
Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #ACR22 Abstr#1282 https://t.co/3VyJR6k76U https://t.co/VM5rnbmv9h
Richard Conway RichardPAConway ( View Tweet)